at220

AT220 is a novel and differentiated formulation of a biosimilar biologic, developed using Arecor's proprietary Arestat technology platform. It is designed to improve the physical properties and features of an existing reference biologic, enabling enhanced product performance such as stability or administration. The exact reference biologic for this biosimilar has not been publicly disclosed, but industry analysts suggest it is likely a formulation of tocilizumab, a monoclonal antibody indicated for autoimmune and inflammatory diseases. AT220 was developed in partnership with a global pharmaceutical company. It is the first commercial product incorporating Arestat technology and has launched in Europe, triggering commercial sales and royalty payments to Arecor[1][3][5][7][9].

Brand names

AT220AT-220AT 220

Other names

AT220AT-220AT 220